期刊文献+

孟鲁司特钠咀嚼片含量测定及初步稳定性研究 被引量:5

Assay of montelukast sodium chewable tablets and preliminary stability
下载PDF
导出
摘要 目的为实现对孟鲁司特钠咀嚼片质量的关键指标的控制和制剂稳定性研究。方法建立一种专属性好,灵敏度高,快速,准确的HPLC分析方法,测定3批次孟鲁司特钠咀嚼片中孟鲁司特钠含量;并通过高温、高湿度、强光照射试验和加速试验及长期稳定性试验,进行制剂的初步稳定性试验。结果建立的方法经验证,孟鲁司特钠的线性范围为0.5~16.0μg/mL,检测限为0.12μg/mL,定量限为0.39μg/mL,平均加样回收率分别是99.7%、101.2%和99.8%,精密度试验RSD值为1.04%、1.23%和1.27%,初步稳定性试验中含量变化的RSD值均为1.22%、1.67%和1.45%。结论该方法分析时间短、专属性好、准确度高,可用于孟鲁司特钠咀嚼片中孟鲁司特钠含量测定。孟鲁司特钠咀嚼片质量稳定,符合要求。 Objective To achieve quality control of montelukast sodium chewable tablets for the key factors and the stability studies of preparation. Methods A good specificity,high sensitivity,fast and accurate HPLC method has been established and applied to the determination of montelukast sodium assay in three batches of montelukast sodium chewable tablets and the preliminary stability test of the preparation has been explored through the high temperature,high humidity,bright light test and accelerated test as well as long-term stability test. Results The established method has been validated,and the linear range of sufentanil is 0.5~16.0μg/mL,the limit of determination is 0.12μg/mL and the limit of quantification is 0.391.L g/mL,the average recoveries are 99.7%,101.2 % and 99.8%,RSD values of the precision is 1.04%,1.23% and 1.27%. RSD values of the preliminary stability test is 1.22%,1.67% and 1.45%. Conclusion The analysis time of the method is short and the method has high specificity,accuracy,can be used for assay of montelukast sodium chewable tablets. The quality of montelukast sodium chewable tablets is stable and meets the requirements.
出处 《中国医药科学》 2012年第19期89-91,共3页 China Medicine And Pharmacy
关键词 孟鲁司特钠 咀嚼片 含量测定 稳定性试验 Montelukast sodium Chewable tablets Assay Stability test
  • 相关文献

参考文献10

  • 1Nayak A.A review of montelukast in the treatment of asthma and allergicrhinitis[J].Expert Opin Pharmacother,2004,5 ( 3 ): 679.
  • 2Wahn U, Dass SB. Review Of recent re, suits of montelukast use as a monotherapy in children with mild asthma[J]. Clinical Therapeutics, 2008,30:1026.
  • 3Mechiche H, Candenas L, Pinto FM, el al. Characterization of cysteinyl leukntriene receptors on human saphenous veins: antagonist activity of monteluka.st and its metabolites[J].J Cardiovasc Pharmacol, 2004,43 ( 1 ) : 113.
  • 4Orudam M, JWatase TM, Mezawa A, et al.The role of leukotriene D4 in allergic rhinitis[J].Ann Allergy, 1988,60 ( 6 ) : 537.
  • 5Kohif, Miyagawa H, Agrawal D, et al. Genermion of leukotriene B4 and C4 from granulocytes of normal controls, allergic rhinitis, and asthmatic sabjects[J].Ann Allergy, 1990,65 ( 3 ): 228.
  • 6黄晓英,应宗友.孟鲁司特钠治疗咳嗽变异性哮喘的临床观察[J].实用巾西医结合临床,2008,8(8):18.
  • 7Ferreri N, Howland W, Stevenson D, et al.Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin[J].The American review of respiratory disease, 1988, 137 ( 4 ): 847.
  • 8孙晓红,简国江,张燕丽,梁玉兰.孟鲁司特钠治疗毛细支气管炎临床疗效观察[J].儿科药学杂志,2010(1):27-28. 被引量:21
  • 9王玉芳,安肃英.孟鲁司特钠对毛细支气管炎临床疗效的研究[J].临床荟萃,2010,25(14):1271-1272. 被引量:6
  • 10Patil S, Pore YV. Determination of Montelukast Sodium and Bambuterol Hydrochloride in Tablets using RP HPLC[J].Indian journal of pharmaceutical sciences,2009,71 ( 1 ): 58.

二级参考文献14

  • 1陈福将,李昌崇,罗运春,陈小芳.毛细支气管炎患儿血清MCP-4、MDC和IL-4水平及临床意义[J].临床儿科杂志,2007,25(5):361-363. 被引量:14
  • 2沈晓明,王卫平.儿科学[M].第七版.北京:人民卫生出版社,2008.153.
  • 3张梓荆,申昆玲.毛细支气管炎[M]//胡亚美,江载劳.诸福棠实用儿科学.7版.北京:人民卫生出版社,2005:1199-1201.
  • 4Wang EE, Milner R, Alien U, et al. Bronchodilators for treatment of mild hronchiolitis:a factorial randomised trial[J]. Arch Dis Child,1992,67(3):289-293.
  • 5hegg JP, Hussain IR, Warner JA, et al. Type 1 and type 2 eytokine imbalance in acute respiratory syncytiaI virus bronchiolitis[J]. Am J Respir Crit Care Med, 2003,168(6) : 633- 639.
  • 6Maeba S, Ichiyama T, Ueno Y, et al. Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules[J]. Ann Allergy Asthma lmmunol,2005,94(6):670- 674.
  • 7Godiska R, Chantry D, Raport CJ, et al. Monocyte chemotactic protein-4:tissue specific expression and signaling through CC ebemokine receptors2 [J]. J Leukoe Biol, 1997,61 (3) : 353-360.
  • 8Migoya E, Kearns GI., Hartford A, et al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old[J]. J Clin Pharmacol,2004,44(5) :487- 494.
  • 9Kearns GI.,Lu S,Maganti L,et al. Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis[J]. J Clin Pharmacol,2008,48(4):502-511.
  • 10Knorr B, Maganti L, Ramakrishnan R, et al. Pharmacokinetics and safely of montelukast in children aged 3 to 6 months[J]. J Clin Pharmaeol,2006,46(6) :620- 627.

同被引文献44

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部